Pharma channel feed

FDA ex­perts wave through Pfiz­er's copy­cat of an ane­mia med from Am­gen, J&J, but a le­gal chal­lenge still re­mains

9 years ago

Scott Got­tlieb has some ideas about block­ing any more would-be Mar­tin Shkrelis from price goug­ing

9 years ago

Right on the heels of a PhI­II fail­ure, Mer­ck neu­ro­science dou­bles down with a new drug tar­get­ing tau

9 years ago

Mys­tery biotech Em­maus grabs ground­break­ing FDA pan­el back­ing for sick­le cell drug — af­ter qui­et­ly scrap­ping $225M deal

9 years ago

Puma wins a big round in fight for ner­a­tinib OK as ex­perts of­fer a cru­cial thumbs up

9 years ago

No­var­tis swings the ax again, this time aim­ing at 250 job cuts in the US

9 years ago
R&D

The FDA re­fus­es to lift a clin­i­cal hold on Cel-Sci’s PhI­II drug

9 years ago
R&D

Pi­o­neer­ing Mer­ck makes an­oth­er break­through with PD-1 star Keytru­da, grab­bing first OK for a can­cer bio­mark­er

9 years ago

Pfiz­er grabs a sol­id en­dorse­ment from FDA in­sid­ers for their knock­off of Am­gen’s flag­ship drug Epogen

9 years ago

Trump ad­min­is­tra­tion dou­bles down on slash­ing the bud­get at NIH, FDA — with a user fee hike for bio­phar­ma

9 years ago
People
R&D

Re­gen­eron, Sanofi win a de­layed OK for rheuma­toid arthri­tis IL-6 heavy­weight sar­ilum­ab

9 years ago

FDA re­view rais­es some se­ri­ous ques­tions for Puma, but shares rock­et up on pos­i­tive notes

9 years ago

Top an­a­lyst says the tem­pest over drug prices will like­ly just die out with­out any ma­jor changes

9 years ago
R&D

The EMA re­jects XBiotech’s can­cer drug af­ter an em­bar­rass­ing PhI­II — but they’re not giv­ing up

9 years ago
R&D

Mer­ck’s check­point star Keytru­da grabs an­oth­er FDA OK, steer­ing past wreck­age of a Roche dis­as­ter

9 years ago

No­var­tis is send­ing 500 jobs to the scrap heap while adding 350 ‘high-tech’ po­si­tions for growth

9 years ago
R&D

Gly­coMimet­ics stock rock­ets up on the lat­est ‘break­through’ ti­tle in can­cer R&D

9 years ago

Ab­b­Vie los­es a round in the heavy­weight biosim­i­lar fight over Hu­mi­ra patents

9 years ago

FDA forces Con­cert Phar­ma to hit the brakes on a mid-stage study so it can re­view tox stud­ies

9 years ago
R&D

FDA shoves Bay­er’s lym­phoma drug co­pan­lis­ib in­to the spot­light with its promise of a speedy re­view

9 years ago

Over­wrought mar­ket­ing? Ads, not re­search, cre­ate some phar­ma best-sell­ers

9 years ago

X-Chem forges an­oth­er dis­cov­ery deal, this time with Ver­tex

9 years ago

FDA com­mis­sion­er Scott Got­tlieb sets some goals: Find ways to low­er drug prices, use new tech to speed de­vel­op­ment

9 years ago

Ake­bia adds $50M deal with Vi­for for ex­clu­sive US dis­tri­b­u­tion deal for vadadu­s­tat

9 years ago
First page Previous page 325326327328329330331 Next page Last page
A service from the Financial Times